Business
Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023
CAMBRIDGE, Mass., Oct. 18, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of
About this update from Akebia Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Oct. 18, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the American Society of Nephrology Kidney Week 2023 (ASN Kidney Week), which will take place at the Pennsylvania Convention Center in Philadelphia from November 2-5, 2023. \n\n \n \n \n \n \n \n\n \nAkebia-supported posters will be presented at ASN Kidney Week on November 2, 2023, from 10:00 a.m. – 12:00 p.m. EST. Abstracts are available here. ASN Kidney Week attendees can also visit Akebia at Booth #2515 in the Exhibit Hall. \nNotably, Akebia will present a poster with data on alternate dosing for vadadustat, its investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. Akebia resubmitted a New Drug Application for vadadustat as a daily treatment to the U.S. Food and Drug Administration in late September and expects a Prescription Drug User Fee Act (PDUFA) date to be assigned before the end of October. \nSafety and Efficacy of Vadadustat Thrice Weekly in Patients with Anemia Due to Dialysis-Dependent Chronic Kidney Disease - Poster Board #: TH-PO983\nRandomized Assessment of Auryxia® (ferric citrate) Therapy for In-Center and Home Dialysis Patients - Poster Board #: TH-PO967\nHospitalizations and RBC Transfusions in Patients with DD-CKD on Auryxia® (ferric citrate) Compared to Other Phosphate Binders - Poster Board #: TH-PO973\nSafety and Tolerability of Auryxia® (ferric citrate) in Children with Hyperphosphatemia Related to Chronic Kidney Disease - Poster Board #: INFO12-TH\nDecision Tree Model Simulating the Burden of Hyperphosphatemia in U.S. Adult Patients with ESKD on Dialysis - Poster Board #: TH-PO139\nAbout Akebia TherapeuticsAkebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.\nAbout VadadustatVadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to mimic the physiol...